Veres Gábor, Szabó Dolóresz, Várkonyi Agnes, Tari Beáta, Polgár Marianne, B Kovács Judit, Horváth Agnes, Tomsits Erika, Tokodi István, Bodánszky Hedvig, Dezsofi Antal, Szakos Erzsébet, Vass Noémi, Ruszinkó Viktória, Kovács Márta, Müller Katalin Eszter, Arató András
Semmelweis Egyetem, Altalános Orvostudományi Kar, I. Gyermekgyógyászati Klinika, Budapest, Bókay J. u. 53., 1083.
Orv Hetil. 2010 Jan 31;151(5):179-83. doi: 10.1556/OH.2010.28792.
Infliximab, the chimeric antibody to tumor necrosis factor-alpha, is indicated for medically refractory pediatric Crohn disease. Aim of our study was to examine the efficacy and side effects of infliximab therapy in Hungarian pediatric patients with Crohn disease since the authorisation of medicine for children to 31.12.2008. 23 children with refractory Crohn disease received infliximab during this period. Induction therapy with 5 mg/kg infliximab at weeks 0, 2, and 6 was introduced. 18 patients (81.8%) achieved clinical response, and 13 patients (59.1%) were in remission at the 6th week of the observation period. The evaluation was based on data of 22 children. Fistula closure rate was 70% at the at the 6th week. Two patients had acute infusion reaction, one had severe anaphilactic reaction after infliximab infusion. Chronic side effects were also observed in three cases. In our study infliximab induction therapy was effective in most pediatric patients with therapy refractory Crohn disease.
英夫利昔单抗是一种抗肿瘤坏死因子-α的嵌合抗体，适用于药物治疗无效的儿童克罗恩病。我们研究的目的是自该药物获批用于儿童以来至2008年12月31日，考察英夫利昔单抗治疗匈牙利儿童克罗恩病患者的疗效和副作用。在此期间，23例难治性克罗恩病患儿接受了英夫利昔单抗治疗。采用在第0、2和6周给予5mg/kg英夫利昔单抗的诱导治疗方案。18例患者（81.8%）获得临床缓解，13例患者（59.1%）在观察期第6周时处于缓解状态。评估基于22例患儿的数据。瘘管闭合率在第6周时为70%。2例患者出现急性输注反应，1例在输注英夫利昔单抗后发生严重过敏反应。还观察到3例慢性副作用。在我们的研究中，英夫利昔单抗诱导治疗对大多数难治性儿童克罗恩病患者有效。
